Equity Profile

CSTL

Castle Biosciences, Inc.

Health CareHealth Care Services$933.3M

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on developing and commercializing diagnostic tests for skin cancer and other diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.30

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$90M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CSTL Q2-2026 Earnings Preview

Context

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on developing and commercializing diagnostic tests for skin cancer and other diseases. With a market cap of $1 billion, it plays a significant role in the healthcare services sector, particularly in personalized medicine and cancer diagnostics.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.24%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, Castle Biosciences reported an EPS of $-0.49, which was better than the expected $-0.56, leading to a positive stock reaction of +0.61% the next day. However, revenue details were not disclosed, leaving some uncertainty.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Castle Biosciences to report a loss of $-0.30 per share on $90 million in revenue for Q2-2026. The market is closely watching how the company continues to navigate its growth in the competitive healthcare landscape.

Bull Case

If Castle can exceed revenue expectations and improve its EPS, it could signal strong demand for its diagnostic tests, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could raise concerns about its growth trajectory and market position.

Key Metrics to Watch

EPS

$-0.30

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$90M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Castle Biosciences achieve revenue of at least $90 million this quarter?

Meeting or exceeding this revenue target could indicate strong market demand for its products and boost investor confidence.

What specific steps is management taking to improve EPS from the current consensus of $-0.30?

Investors will be looking for actionable insights into how the company plans to enhance profitability moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the demand for Castle's diagnostic tests, as recent trends in skin cancer diagnoses suggest increasing awareness and testing.

Supporting Evidence

Castle's recent product launches have received positive feedback from healthcare professionals, indicating potential for higher sales.

The company's historical performance shows a strong ability to surprise on the upside, with an 88% EPS beat rate.

Options pricing indicates a significant expected move, suggesting that traders anticipate a more volatile reaction than the consensus forecasts.

Key Risk

If revenue comes in below $89 million, it could undermine the bullish narrative surrounding the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Castle's ability to grow revenue while managing costs effectively, which will be crucial for future profitability.

Bull Confirmed If

Revenue exceeding $90 million with an EPS improvement to less than $-0.30 would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.30 or revenue falling below $89 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±29.41%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±29.4% while CSTL has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

88.6%

Calls (300)P/C Ratio: 1.00Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Castle beats expectations, history suggests a potential stock increase of around +1.02%, confirming positive market sentiment.

In-Line / Cautious

An in-line report could lead to muted reactions as investors await further clarity on future guidance.

Miss

If the company misses expectations, history suggests a decline of about -3.10%, which could raise concerns about its growth strategy.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on customer acquisition strategies and growth in key markets.
3Management's outlook on future revenue growth and profitability targets.
4Insights into competitive pressures and how Castle plans to address them.
5Any commentary on regulatory developments that could impact operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on developing and commercializing diagnostic tests for skin cancer and other diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.30

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$90M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CSTL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.24%

Avg Stock Reaction

+0.50%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Castle can exceed revenue expectations and improve its EPS, it could signal strong demand for its diagnostic tests, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could raise concerns about its growth trajectory and market position.

Key Metrics to Watch

EPS

$-0.30

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$90M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Castle Biosciences achieve revenue of at least $90 million this quarter?

Meeting or exceeding this revenue target could indicate strong market demand for its products and boost investor confidence.

What specific steps is management taking to improve EPS from the current consensus of $-0.30?

Investors will be looking for actionable insights into how the company plans to enhance profitability moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the demand for Castle's diagnostic tests, as recent trends in skin cancer diagnoses suggest increasing awareness and testing.

Supporting Evidence

Castle's recent product launches have received positive feedback from healthcare professionals, indicating potential for higher sales.

The company's historical performance shows a strong ability to surprise on the upside, with an 88% EPS beat rate.

Options pricing indicates a significant expected move, suggesting that traders anticipate a more volatile reaction than the consensus forecasts.

Key Risk

If revenue comes in below $89 million, it could undermine the bullish narrative surrounding the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Castle's ability to grow revenue while managing costs effectively, which will be crucial for future profitability.

Bull Confirmed If

Revenue exceeding $90 million with an EPS improvement to less than $-0.30 would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.30 or revenue falling below $89 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±29.41%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±29.4% while CSTL has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

88.6%

Calls (300)P/C Ratio: 1.00Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Castle beats expectations, history suggests a potential stock increase of around +1.02%, confirming positive market sentiment.

In-Line / Cautious

An in-line report could lead to muted reactions as investors await further clarity on future guidance.

Miss

If the company misses expectations, history suggests a decline of about -3.10%, which could raise concerns about its growth strategy.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on customer acquisition strategies and growth in key markets.
3Management's outlook on future revenue growth and profitability targets.
4Insights into competitive pressures and how Castle plans to address them.
5Any commentary on regulatory developments that could impact operations.